ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Latest Government Action





















R&D Insight
Can you help?
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
Dame Sally Davies Tweet


















News from Davos 2020: Some positive signs, but overall a fragile antibiotic market at a tipping point
Developing antibiotics for children: There are no easy answers
Reimbursing for innovative antibiotics / Encouraging updates from the AMR conference
Impact of PASTEUR: 9.9m lives saved, ROI of 125:1
FDA: Early endpoints and late endpoints suggest a path to global regulatory convergence (Bart et al.)
The hunt for oral antibiotics: Beyond Lipinski’s Rule of Five
IDSA White Paper on developing narrow-spectrum antimicrobials + editorial by G. Drusano
Draft EMA antibacterial guidance: Analysis
Global survey of novel antibiotic reimbursement models / PASTEUR Act introduced to US House
FDA workshop: Insights on inhaled antifungals and antibacterials
FDA analysis of 40-years of antibacterial development: Dheman et al.
FDA and EMA regulatory updates / Fireside chat during the 4th AMR Conference
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
Alexander Fleming Tweet

The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
U.S. Senator Michael Bennet Tweet